The consumer-goods company is selling a majority stake in its home-care business to Advent International as it looks to sharpen its focus on core brands. The company reported a second-quarter earnings ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration news is on gender-affirming care for youth, President Donald Trump's vein ...

The agreement, signed Monday between CMS and DHS, has not been announced publicly, AP reports. Other Trump administration ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

London’s FTSE 100 was up 0.2% at 8,986.82 in afternoon trade on Friday. BP was in the black as the oil giant agreed to sell ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

London stocks had pared gains by midday on Friday, with GSK under the cosh. The FTSE 100 was flat at 8,971.33, having ...

London's main stock indexes rose on Friday, with the blue-chip index hovering near record highs, aided by a slew of positive ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.